Sirolimus in the Management of Blue Rubber Bleb Nevus Syndrome: A Case Report and Review of the Literature.

Autor: AlNooh BM; Department of Dermatology, King Saud University and King Khalid University Hospital, Riyadh, Saudi Arabia., AlQadri NG; Department of Dermatology, King Saud Medical City, Riyadh, Saudi Arabia., Alghubayn M; Department of Medicine, King Saud Medical City, Riyadh, Saudi Arabia., AlAjlan SM; Department of Dermatology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Jazyk: angličtina
Zdroj: Case reports in dermatology [Case Rep Dermatol] 2021 Jul 29; Vol. 13 (2), pp. 417-421. Date of Electronic Publication: 2021 Jul 29 (Print Publication: 2021).
DOI: 10.1159/000511535
Abstrakt: Blue rubber bleb nevus syndrome (BRBNS) is a rare multifocal venous malformation (VM) that may affect any tissue or organ but mainly affects the skin, subcutaneous tissue and gastrointestinal (GI) tract. Patients present with serious anemia, treated with lifelong iron supplements and frequent blood transfusion secondary to chronic GI bleeding. Variable therapeutic modalities were used in the management of BRBNS; sirolimus (SRL), a mammalian target of rapamycin (mTOR) inhibitor, is found to be a promising therapy for vascular anomalies.
Competing Interests: The authors have no conflicts of interest to declare.
(Copyright © 2021 by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje